Context The incidental detection of localized renal masses has been rising steadily, but a
significant proportion of these tumors are benign or indolent and, in most cases, do not …

Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α
being developed by Peloton Therapeutics for the treatment of solid tumours, including renal …

Background Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in
clear-cell renal-cell carcinoma in early-phase studies. Methods In a phase 3, multicenter …

Summary Background In the CheckMate 9ER trial, patients with advanced renal cell
carcinoma who received first-line nivolumab plus cabozantinib had significantly better …

Clear-cell renal cell carcinoma (ccRCC) is the most common histological type of RCC. To
investigate the intratumoral heterogeneity of ccRCC, we analyzed single-cell RNA …

Molecular routes to metastatic dissemination are critical determinants of aggressive cancers.
Through in vivo CRISPR–Cas9 genome editing, we generated somatic mosaic genetically …

The clear cell renal cell carcinoma (ccRCC) microenvironment consists of many different cell
types and structural components that play critical roles in cancer progression and drug …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Preclinical models and early clinical data suggest an interplay between the gut microbiome
and response to immunotherapy in solid tumors including metastatic renal cell carcinoma …

Background: Necroptosis, a cell death of caspase-independence, plays a pivotal role in
cancer biological regulation. Although necroptosis is closely associated with oncogenesis …